Results 161 to 170 of about 466,743 (315)
Genetic Code Expanded T Cell for Controllable Immunotherapy
Our GCE‐CAR‐T cells enables tight, dose‐dependent, and function‐preserving control of CAR expression at the translational level through amber codon suppression and genetic incorporation of ncAA. ABSTRACT Chimeric antigen receptor (CAR)‐T cell therapy has demonstrated curative potential against hematologic malignancies, but its clinical application ...
Xue Wang +4 more
wiley +1 more source
MicroRNA dysregulation in B-cell non-Hodgkin lymphoma
Emilia L Lim,1 Marco A Marra1,21Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada; 2Department of Medical Genetics, University of British Columbia, Vancouver, BC, CanadaAbstract: B-cell non-Hodgkin lymphomas ...
Marra MA, Lim EL
core
ABSTRACT Follicular lymphoma (FL) remains an incurable B‐cell malignancy with high relapse rates, and conventional therapies are often limited by significant toxicity, highlighting the need for novel treatments. We identified that FL exhibits markedly low expression of NAD(P)H: quinone oxidoreductase 1 (NQO1), a key enzyme required for activating ...
Jinxing Zhang +10 more
wiley +1 more source
Mucosa associated lymphoid tissue (MALT) lymphomas are low-grade, non-Hodgkin’s B cell lymphomas, mainly occurring in the gastrointestinal tract, but also in other tissues.
Paliogiannis, Panagiotis +5 more
core
ABHD17C‐mediated depalmitoylation of BCL6B at Cys442 blocks its nuclear import and triggers ubiquitin‐dependent degradation, attenuating transcriptional repression of the anti‐phagocytic signal CD24. This mechanism enables pancreatic cancer cells to evade macrophage phagocytosis and fosters an immunosuppressive microenvironment.
Yalu Zhang +9 more
wiley +1 more source
SSR4, a TRAP component induced in B cells, governs BAFFR N‐glycosylation via DDOST to sustain NF‐κB signaling, B‐cell differentiation, and TLS maturation. Its loss impairs anti‐tumor immunity, while overexpression improves antibody glycosylation and ADCC, revealing a critical regulator for cancer immunotherapy.
Wei Zhao +15 more
wiley +1 more source
Tatsuya Yunoki,1 Jun Murakami,2 Yukihiro Imagawa,3 Takahiko Nakajima,4 Atsushi Hayashi1 1Department of Ophthalmology, 2Department of Gastroenterology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, 3Department of ...
Murakami J +4 more
core
Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects
Nucleic acid therapeutics bypass the structural limitations of conventional drugs by targeting mRNA rather than proteins. This review examines how antisense oligonucleotides, siRNAs, miRNAs, aptamers, and mRNA vaccines intervene against historically undruggable oncoproteins including Ras, MYC, and p53, highlighting mechanistic advances, delivery ...
Feng Xu +6 more
wiley +1 more source
This study reveals a metabolic signaling axis in the OSCC microenvironment where palmitic acid (PA) drives the activation of CAFs. PA uptake triggers CEBPG‐dependent epigenetic remodeling to upregulate ERN1 and TMBIM6, thereby mitigating ER stress. This adaptive program sustains CAF survival and the pro‐metastatic phenotype, establishing this pathway ...
Yiling Duan +6 more
wiley +1 more source
Heat Shock Protein 90: From Molecular Chaperone Function to Therapeutic Targeting in Malignancies
In this review, an integrated conceptual framework linking HSP90's molecular chaperone functions to its pathological roles in cancer is proposed. HSP90 serves as a central node that integrates oncogenic signaling, buffers proteotoxic stress, maintains cancer stem cell plasticity, and shapes tumor‐immune interactions, all of which converge to drive ...
Beibei Zhang +4 more
wiley +1 more source

